Oncotarget

Reviews:

Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype

Fangyuan Shao, Heng Sun and Chu-Xia Deng _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:73329-73344. https://doi.org/10.18632/oncotarget.20274

Metrics: PDF 1353 views  |   HTML 2817 views  |   ?  


Abstract

Fangyuan Shao1, Heng Sun1 and Chu-Xia Deng1

1Faculty of Health Sciences, University of Macau, Macau SAR, China

Correspondence to:

Chu-Xia Deng, email: cxdeng@umac.mo

Keywords: cancer therapy, TNBC subtype, CSCs, drug resistance, cancer targets

Received: May 10, 2017     Accepted: August 06, 2017     Published: August 16, 2017

ABSTRACT

Triple-negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer, which is characterized as estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative. TNBC is the most difficult breast cancer subgroup to treat, due to its unresponsiveness to current clinical targeted therapies, high rate of recurrence, and poor prognosis. Thus, there is an urgent medical need to identify therapeutic targets and develop more effective stratified medicine for the treatment of TNBC. Here we review the potential therapeutic targets for TNBC based on its intrinsic subtype. We also review the aberrant activated signals found in different subgroups of TNBC, including androgen receptor (AR) and PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedge-hog, and TGF-β signaling pathways, which play essential roles in multiple development stages of TNBC. The careful analysis of these signaling pathways and therapeutic targets would have significant impact on the drug development and clinical trials, leading to effective therapies for this deadly disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20274